Non-executive director Guo Huaqing increased his holdings of SciClone Pharmaceuticals (02171) by 30,000 shares at a price of HK$14.98 per share.
On December 15th, non-executive director Guo Huaqing increased his holdings in Keji Pharmaceutical (02171) by 30,000 shares, at a price of HK$14.98 per share, with a total amount of HK$449,400.
The latest data from the Hong Kong Stock Exchange shows that on December 15th, non-executive director Guo Huaqing increased his holdings of Keji Medicine (02171) by 30,000 shares, with a price of 14.98 Hong Kong dollars per share, for a total amount of 449,400 Hong Kong dollars. After the increase, the latest number of shares held is approximately 224 million, with a shareholding ratio of 38.75%.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
